Liminatus Pharma regains Nasdaq minimum bid price compliance after 1-for-50 reverse split

Liminatus Pharma, Inc.

Nasdaq notice dated Sept 24, 2026: closing bid price was above $1.00 for 13 consecutive trading days from Aug 21 to Sept 9, 2026; the matter is now closed.
Company effected a 1-for-50 reverse stock split at the close of trading on Aug 20, 2026 to cure the bid price deficiency.
Original Jan 15, 2026 notice: bid below $1.00 for 30 consecutive business days, failing Nasdaq Listing Rule 5450(a)(1) for the Global Market.
Nasdaq Hearings Panel transferred the company to the Nasdaq Capital Market effective Aug 4, 2026 and set a Sept 3, 2026 deadline under Rule 5550(a)(2).

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.